Literature DB >> 11994506

Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.

Mayda Gürsel1, Daniela Verthelyi, Ihsan Gürsel, Ken J Ishii, Dennis M Klinman.   

Abstract

Synthetic oligodeoxynucleotides (ODN) expressing "CpG motifs" show promise as immune adjuvants, antiallergens, anticancer, and immunoprotective agents. Two structurally distinct classes of CpG ODN have been identified that stimulate human PBMC. This work establishes that both types of ODN bind to and are internalized by the same individual B cells, NK cells, and monocytes. However, the intracellular localization of "D" and "K" ODN differs, as does their functional activity: "K" type ODN trigger monocytes and B cells to proliferate and secrete IL-6 and IgM, whereas "D" type ODN induce NK cells to produce IFN-gamma and monocytes to differentiate into CD83(+)/CD86(+) dendritic cells. In monocytes, these two types of ODN (which differ in backbone composition and CpG motif) cross-inhibit one another's activity. Thus, different types of CpG ODN have distinct and in some cases incompatible effects on the same cells, a finding with important implications for the therapeutic use of these agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994506

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  51 in total

1.  Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides.

Authors:  D M Klinman; D Currie
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

2.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

Review 3.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

4.  RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.

Authors:  Johanna E Lee; C Frank Bennett; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

5.  Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Authors:  Cordula Weber; Christian Müller; Anja Podszuweit; Carmen Montino; Jörg Vollmer; Alexandra Forsbach
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

6.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

7.  The Toll-like receptor 9 signalling pathway regulates MR1-mediated bacterial antigen presentation in B cells.

Authors:  Jianyun Liu; Randy R Brutkiewicz
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

8.  Innate immune responses induced by CpG oligodeoxyribonucleotide stimulation of ovine blood mononuclear cells.

Authors:  Angelo Mena; Anil K Nichani; Yurij Popowych; Dale L Godson; Donna Dent; Hugh G G Townsend; George K Mutwiri; Rolf Hecker; Lorne A Babiuk; Philip Griebel
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

9.  CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection.

Authors:  Jane C Deng; Thomas A Moore; Michael W Newstead; Xianying Zeng; Arthur M Krieg; Theodore J Standiford
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

10.  Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides.

Authors:  Ana M Avalos; Eicke Latz; Betty Mousseau; Sean R Christensen; Mark J Shlomchik; Frances Lund; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.